We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Genetics of Schizophrenia

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2008 by Sheba Medical Center.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00619437
First Posted: February 21, 2008
Last Update Posted: February 21, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Sheba Medical Center
  Purpose
Genetic etiology in schizophrenia is widely accepted. However, many chromosomal sites were shown to characterize the families of patients with schizophrenia. This is probably due to the high genetic heterogenity of this illness. Thus, it is important to investigate the genetic factor in relatively genetically homogenous populations. Many studies have indicate that Ashkenazy Jews show relative gentic homogenity. Indeed, the genes responsible for most Mendelian disorders of Jewish peoples have been identified. The study will apply genome-wide mutation screening methods to identify candidate allells in subjects of Ashkenazi Jewish ancestry with multiplex schizophrenia.

Condition
Schizophrenia

Study Type: Observational
Study Design: Observational Model: Family-Based
Time Perspective: Prospective
Official Title: Genetics of Schizophrenia

Resource links provided by NLM:


Further study details as provided by Sheba Medical Center:

Biospecimen Retention:   Samples With DNA
Cell Lines / DNA

Estimated Enrollment: 100
Study Start Date: April 2008
Estimated Study Completion Date: December 2009
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 78 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
schizophrenia
Criteria

Inclusion Criteria:

  1. Age 18+;
  2. Meet DSM-IV criteria for Schizophrenia;
  3. At least one first-degree relative who Meet DSM-IV criteria for Schizophrenia;
  4. Can sign the informed consent form.

Exclusion Criteria:

  1. Patients suffering from terminal or incurabale disease;
  2. Minors, incompetents
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00619437


Contacts
Contact: Raz Gross, MD, MPH 972 3 530 3962 razg@gertner.health.gov.il

Locations
Israel
Sheba Medical Center Not yet recruiting
Tel Hashomer, Israel
Contact: Michael Bunzel, MD         
Principal Investigator: Michael Bunzel, MD         
Sponsors and Collaborators
Sheba Medical Center
Investigators
Study Director: Michael Bunzel, MD Psychiatric ward, Sheba Medical Center
  More Information

Responsible Party: Raz Gross, Head, Mental Health Epidemiology, The Gertner Institute for Epidemiology
ClinicalTrials.gov Identifier: NCT00619437     History of Changes
Other Study ID Numbers: SHEBA-07-4620-RG-CTIL
First Submitted: February 10, 2008
First Posted: February 21, 2008
Last Update Posted: February 21, 2008
Last Verified: February 2008

Keywords provided by Sheba Medical Center:
schizophrenia
genetics
family
multiplex
haplotypes

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders


To Top